5 things to know about Lagevrio, a new oral treatment for eligible patients with mild to moderate COVID-19

5 things to know about Lagevrio, a new oral treatment for eligible patients with mild to moderate COVID-19

This advertorial has been commissioned and developed by MSD New Zealand
2 minutes to Read
Lagevrio white space

Eligible New Zealand patients now have access to a new way to fight back against COVID-19.1

Lagevrio® (molnupiravir) has provisional consent for the treatment of mild to moderate COVID-19 in adults (≥18 years) who are at increased risk of progressing to severe COVID-19, hospitalisation or death.1

Here are 5 important things to know about Lagevrio

1. Administer as soon as possible after a diagnosis of COVID-19 and within 5 days of symptom onset1

The recommended dose of Lagevrio in adult patients is 800 mg (four 200 mg capsules) taken orally every 12 hours for 5 days, with or without food.1

We are developing a patient information resource in several languages that explains the important information about Lagevrio.

2. No drug interactions (based on limited available data)1

NHC (n-hydroxycytidine), the hydrolysed form of Lagevrio, is not a substrate of major drug metabolising enzymes or transporters. Neither Lagevrio nor NHC are inhibitors or inducers of major drug metabolising enzymes or transporters. Therefore, the potential for LAGEVRIO or NHC to interact with concomitant medications is considered unlikely.1

3. Pregnancy, Breastfeeding and Contraception

Lagevrio is not recommended during pregnancy or breastfeeding (during treatment and for 4 days after the last dose). Please see below for the recommendations for male and female contraception or refer to the Data Sheet.1

4. No dose adjustments recommended1

No dose adjustments are recommended for elderly patients, or for patients with renal or hepatic impairment1.

5. Lagevrio is fully funded for eligible patients2

Lagevrio is funded if the patient meets the Access Criteria for oral antiviral COVID-19 treatment (as per Pharmac’s website) and the prescriber has endorsed the prescription. The supply of treatment is via Pharmac’s approved distribution process.2

Details on the Access Criteria is available at:

https://pharmac.govt.nz/news-and-resources/covid19/covid-oral-antivirals/

Information for people at risk of severe COVID-19 can be found on the Ministry of Health website, available at:

https://www.health.govt.nz/covid-19-novel-coronavirus/covid-19-information-specific-audiences/covid-19-higher-risk-people

Do you need patient resources for your surgery?

Patient education and awareness are important, so MSD is developing a range of surgery resources to help, including patient information (in several languages), brochures and posters.

If you have any questions about Lagevrio, please call 0800 500 673 or email dpoc.australia@msd.com.

Other information

Lagevrio® (molnupiravir) is a Prescription Medicine and is available as 200 mg capsules.

Please review the Lagevrio Data Sheet before prescribing. The Data Sheet is available at www.medsafe.govt.nz.

CONTRAINDICATIONS: Hypersensitivity to the active substance or to any of the excipients.

PRECAUTIONS: Use in pregnancy is not recommended; consider the need for a pregnancy test before initiating treatment in women of childbearing potential who are sexually active. It is recommended that sexually active women of childbearing potential use contraception during and for 4 days after the last dose, and that men who are sexually active with a partner of childbearing potential use an adequate form of contraception during and for 3 months after treatment. Breastfeeding is not recommended during treatment and for 4 days after the last dose. Safety and efficacy of Lagevrio have not been established in patients ≤ 18 years, therefore use in paediatric patients is not recommended. Hypersensitivity reactions have been reported; if signs and symptoms of a clinically significant hypersensitivity reaction occur, immediately discontinue Lagevrio and initiate appropriate medications and/or supportive care.

INTERACTIONS: No drug interactions have been identified based on the limited available data. Potential for interaction with concomitant medications is considered unlikely.

ADVERSE EVENTS: Common: diarrhoea, nausea, dizziness. The following have been reported in post-marketing experience:hypersensitivity, angioedema, erythema, rash, urticaria.

DOSAGE AND ADMINISTRATION: Adults: 800 mg (four 200 mg capsules) taken orally every 12 hours for 5 days, with or without food. Safety and efficacy when administered for periods longer than 5 days have not been established. Lagevrio should be administered as soon as possible after a diagnosis of COVID-19 has been made and within 5 days of symptom onset. Based on Data Sheet dated 14 April 2022.

Merck Sharp & Dohme (New Zealand) Limited. Level 3, 123 Carlton Gore Road, Newmarket, Auckland.

Copyright © 2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

NZ-LAG-00012. First issued May 2022. TAPS DA2208KN.

References

1. Lagevrio Data Sheet.

2. Pharmac. Pharmaceutical Schedule. Available at: https://schedule.pharmac.govt.nz/ScheduleOnline.php. Accessed on: 26 Apr 2022.